title: Interleukin-17A is involved in enhancement of tumor progression in murine intestine.
abstract: Interleukin (IL)-17A is a cytokine involved in neutrophilic inflammation but the role of IL-17A in anti-tumor immunity is controversial because both pro- and anti-tumor activities of IL-17A have been reported. We hypothesized that constitutive expression of IL-17A in intestinal environment modifies tumor growth. To address the issue, mice were inoculated into subserosa of cecum (i.c.) with murine EL4 lymphoma expressing a model tumor antigen, and tumor growth was monitored. IL-17A-producing cells were detected both in tumor mass and in normal intestinal tissue of i.c. tumor-bearing wild type mice. Tumor size in the wild-type mice was significantly higher than that in the cecum of IL-17A gene-knockout mice. Furthermore, anti-IL-17A monoclonal antibody treatment of wild-type mice resulted in decreased tumor size in the cecum. Model tumor-antigen-specific interferon-γ production was not modified in draining mesenteric lymph node cells in the absence or after neutralization of IL-17A. All the results suggest that constitutive expression of IL-17A in intestine enhances tumor growth, and anti-IL-17A antibody treatment is a candidate of a new anti-tumor immunotherapy against intestinal tumors.
authors.affiliation: First Department of Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
authors.forename: Kiyotetsu
authors.initials: K
authors.lastname: Oshiro
authors.forename: Hideyasu
authors.initials: H
authors.lastname: Kohama
authors.forename: Masayuki
authors.initials: M
authors.lastname: Umemura
authors.forename: Catherine
authors.initials: C
authors.lastname: Uyttenhove
authors.forename: Kyoko
authors.initials: K
authors.lastname: Inagaki-Ohara
authors.forename: Takeshi
authors.initials: T
authors.lastname: Arakawa
authors.forename: Mamoru
authors.initials: M
authors.lastname: Harada
authors.forename: Susumu
authors.initials: S
authors.lastname: Nakae
authors.forename: Yoichiro
authors.initials: Y
authors.lastname: Iwakura
authors.forename: Tadashi
authors.initials: T
authors.lastname: Nishimaki
authors.forename: Goro
authors.initials: G
authors.lastname: Matsuzaki
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000008:administration & dosage* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000276:immunology; D002432:Cecum / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D015870:Gene Expression / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D007371:Interferon-gamma / Q000096:biosynthesis / Q000276:immunology; D020381:Interleukin-17 / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D007414:Intestinal Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D008223:Lymphoma / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D012704:Serous Membrane / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: D057134:Antibodies, Neutralizing; D014408:Biomarkers, Tumor; D020381:Interleukin-17; D007371:Interferon-gamma